Click here for slides on this topic


Phentermine/Topiramate

A treatment for chronic weight management, marketed as Qsymia® (phentermine and topiramate extended release), that is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Refer to full prescribing information.
The following content matched the glossary term: Phentermine/Topiramate

Endocrine Society obesity clinical practice guideline

Top

Summary of guidelines for managing obesity with pharmacologic therapy from the Endocrine Society.

Weight-loss therapy in type 2 diabetes effects of phentermine and topiramate extended-release

Top

Exclusive! Expert diabetes blog post from Silvio Inzucchi, MD. Garvey WT, Ryan DH, Bohannan NJV, et al. Weight loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37(12):3309-3316.

NDEI.org Expert Commentary on Type 2 Diabetes Prevention in SEQUEL from Vivian Fonseca

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on type 2 diabetes prevention in a substudy of SEQUEL: “Weight loss alone may be an option to prevent type 2 diabetes”

Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on SEQUEL. Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912-921.

SEQUEL: Longer-Term Safety, Efficacy of Phentermine + Topiramate for Weight Reduction Among Overweight or Obese Individuals with Cardiometabolic Disease

Top

Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308. The SEQUEL study, an extension of the CONQUER study,1 was a double-blind, placebo-controlled study that evaluated the longer-term efficacy and safety of once-daily, controlled-release phentermine plus topiramate, as an adjunct to lifestyle modification, among overweight and obese subjects with cardiometabolic disease.

CONQUER: Safety, Efficacy of Phentermine + Topiramate for Weight Reduction Among Overweight or Obese Individuals with Weight-Related Comorbidities

Top

Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352. The CONQUER study was a randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of once-daily, controlled-release phentermine plus topiramate for weight reduction among those who were overweight or obese and had weight-related comorbidities.



Slide Library Results

Search Results for: PhentermineTopiramate Slides Found: 0